Privia Health Group, Inc.

Previous wording

• Net income attributable to Privia Health Group, Inc. was $4.2 million and $3.0 million, for the three months ended March 31, 2025 and 2024, respectively.

Current wording

• Net income attributable to Privia Health Group, Inc. was $2.7 million and $3.5 million, for the three months ended June 30, 2025 and 2024, respectively and$6.9 million and $6.5 million for thesix months ended June 30, 2025 and 2024, respectively.

Previous wording

We generate FFS-patient care revenue when we collect reimbursements for FFS medical services provided by Privia Providers. Our agreements with our providers have a multi-year term length and we have historically experienced a 96% provider retention rate, both of which lead to a highly predictable and recurring revenue model. Our FFS contracts with payer partners typically contain annual rate inflators and enhanced commercial FFS rates given our scale in each of our markets. As a result of receiving these rate inflators and enhancements, if we continue to be successful in expanding our provider base, we expect revenue will grow year-over-year in absolute dollars. In addition, in our FFS-patient care revenue, we include collections generated from ancillary services such as clinical laboratory, imaging and pharmacy operations. We also generate FFS-administrative services revenue by providing administration and management services to medical groups which are not owned or consolidated by us. FFS-patient care revenue represented 64.9% and 66.2% of total revenue for the three months ended March 31, 2025 and 2024, respectively. FFS-administrative services revenue represented 6.7% and 7.0% of total revenue for the three months ended March 31, 2025 and 2024, respectively.

Current wording

We generate FFS-patient care revenue when we collect reimbursements for FFS medical services provided by Privia Providers. Our agreements with our providers have a multi-year term length and we have historically experienced a 96% provider retention rate, both of which lead to a highly predictable and recurring revenue model. Our FFS contracts with payer partners typically contain annual rate inflators and enhanced commercial FFS rates given our scale in each of our markets. As a result of receiving these rate inflators and enhancements, if we continue to be successful in expanding our provider base, we expect revenue will grow year-over-year in absolute dollars. In addition, in our FFS-patient care revenue, we include collections generated from ancillary services such as clinical laboratory, imaging and pharmacy operations. We also generate FFS-administrative services revenue by providing administration and management services to medical groups which are not owned or consolidated by us. FFS-patient care revenue represented 63.6% and 65.3% of total revenue for the three months ended June 30, 2025 and 2024, respectively, and 64.2% and 65.7% for the six months ended June 30, 2025 and 2024, respectively. FFS-administrative services revenue represented 6.7% and 7.6% of total revenue for the three months ended June 30, 2025 and 2024, respectively, and 6.7% and 7.3% for the six months ended June 30, 2025 and 2024, respectively.

Previous wording

Over time, we create incremental value for our provider partners by enabling them to succeed in VBC arrangements. We generate VBC revenue when our providers are reimbursed through traditional FFS Medicare, MSSP, Medicare Advantage, commercial payers and other existing and emerging direct payer and employer contracting programs. Given recent regulatory and utilization headwinds in Medicare Advantage, during the first quarter of 2024, the Company renegotiated certain capitation agreements for more favorable contract structures. The revenue is primarily collected in the form of (i) Capitated revenue earned by providing healthcare services to Medicare Advantage attributed beneficiaries for a defined group of services including professional, institutional and pharmacy through a contract that is typically known as an “at-risk contract,” (ii) Shared savings earned based on improved quality and lower cost of care for our attributed lives in VBC incentive arrangements and (iii) Care management fees to cover costs of services typically not reimbursed under traditional FFS payment models, including population management, care coordination, advanced technology and analytics. VBC revenue represented 27.9% and 26.3% of total revenue for the three months ended March 31, 2025 and 2024, respectively.

Current wording

Over time, we create incremental value for our provider partners by enabling them to succeed in VBC arrangements. We generate VBC revenue when our providers are reimbursed through traditional FFS Medicare, MSSP, Medicare Advantage, commercial payers and other existing and emerging direct payer and employer contracting programs. Given recent regulatory and utilization headwinds in Medicare Advantage, during the first quarter of 2024, the Company renegotiated certain capitation agreements for more favorable contract structures. The revenue is primarily collected in the form of (i) Capitated revenue earned by providing healthcare services to Medicare Advantage attributed beneficiaries for a defined group of services including professional, institutional and pharmacy through a contract that is typically known as an “at-risk contract,” (ii) Shared savings earned based on improved quality and lower cost of care for our attributed lives in VBC incentive arrangements and (iii) Care management fees to cover costs of services typically not reimbursed under traditional FFS payment models, including population management, care coordination, advanced technology and analytics. VBC revenue represented 29.3% and 26.6% of total revenue for the three months ended June 30, 2025 and 2024, respectively, and 28.6% and 26.5% for the six months ended June 30, 2025 and 2024, respectively.

Previous wording

The remainder of our revenue is derived from leveraging our existing base of providers and patients to deliver value-oriented services such as virtual visits, virtual scribes and coding. Other revenue represented 0.5% of total revenue for both the three months ended March 31, 2025 and 2024, respectively.

Current wording

The remainder of our revenue is derived from leveraging our existing base of providers and patients to deliver value-oriented services such as virtual visits, virtual scribes and coding. Other revenue represented 0.4% and 0.5% of total revenue for the three months ended June 30, 2025 and 2024, respectively, and 0.4% and 0.5% for the six months ended June 30, 2025 and 2024, respectively.

Previous wording

In November 2024, the Company announced it had entered into the Indiana market through the acquisition of an independent group practice, renamed Privia Medical Group Indiana, LLC (“PMG IN”).

Current wording

In November 2024, the Company announced it had entered into the Indiana market through the acquisition of an independent group practice, renamed Privia Medical Group Indiana, LLC (“PMG IN”), whereby Privia acquired majority ownership in PMG IN.

Previous wording

At the beginning of 2025, the total number of Privia-owned ACOs was nine, serving beneficiaries across the District of Columbia and eleven states, including California, Connecticut, Florida, Georgia, Maryland, Montana, North Carolina, Tennessee, Texas, Virginia, and Washington state.

Current wording

At the beginning of 2025, the total number of Privia-owned ACOs is nine, serving beneficiaries across the District of Columbia and eleven states, including California, Connecticut, Florida, Georgia, Maryland, Montana, North Carolina, Tennessee, Texas, Virginia, and Washington state.

Previous wording

We expect to continue focusing on long-term growth through investments in our sales and marketing, our technology-enabled platform, and our operations. In addition, as we continue our efforts to move markets toward VBC, we expect to continue making additional investments in operations for an expanded suite of clinical capabilities to manage our patient population.

Current wording

We expect to continue focusing on long-term growth through investments in our sales and marketing, our technology stack, and our operations. In addition, as we continue our efforts to move markets toward VBC, we expect to continue making additional investments in operations for an expanded suite of clinical capabilities to manage our patient population.

Previous wording

We launched Privia Care Partners on January 1, 2022 to offer a more flexible affiliation model for providers who do not desire to join one of our Medical Groups. This model aggregates providers in certain of our existing markets as well as new markets who are looking solely for VBC solutions without the necessity of changing EMR providers. We furnish population health services, reporting and analytics to such providers along with a menu of management services from which providers may choose. We continue to have Privia Care Partners’ providers transitioning to our Privia Medical Group model, which demonstrates the flexibility of our operating model and technology platform, as well as the ability to support physicians wherever they are in their transition value-based care.

Current wording

We launched Privia Care Partners on January 1, 2022 to offer a more flexible affiliation model for providers who do not desire to join one of our Medical Groups. This model aggregates providers in certain of our existing markets as well as new markets who are looking solely for VBC solutions without the necessity of changing EMR providers. We furnish population health services, reporting and analytics to such providers along with a menu of management services from which providers may choose. We continue to have Privia Care Partners’ providers transitioning to our Privia Medical Group model, which demonstrates the flexibility of our operating model and technology stack, as well as the ability to support physicians wherever they are in their transition value-based care.

Previous wording

We define Implemented Providers as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by Privia Health and bill for medical services, in both Owned and Non-Owned Medical Groups during that period. This includes, but is not limited to, physicians, physician assistants, and nurse practitioners. We believe that growth in the number of Implemented Providers is a key indicator of the performance of our business and expected revenue growth. This growth depends, in part, on our ability to successfully add new practices in existing markets and expand into new markets. The number of Implemented Providers increased 11.7% as of March 31, 2025 compared to March 31, 2024, due to organic growth in our healthcare delivery business as well as our entrance into the Indiana market.

Current wording

We define Implemented Providers as the total of all service professionals on our platform at the end of a given period who are credentialed by Privia Health and bill for medical services, in both Owned and Non-Owned Medical Groups during that period. This includes, but is not limited to, physicians, physician assistants, and nurse practitioners. We believe that growth in the number of Implemented Providers is a key indicator of the performance of our business and expected revenue growth. This growth depends, in part, on our ability to successfully add new practices in existing markets and expand into new markets. The number of Implemented Providers increased 13.8% as of June 30, 2025 compared to June 30, 2024, due to organic growth in our healthcare delivery business as well as our entrance into the Indiana and Arizona markets.

Previous wording

We define Attributed Lives as any patient that a payer deems attributed to Privia to deliver care as part of a VBC arrangement through a provider of primary care services as of the end of a particular period. The number of Attributed Lives is an important measure that impacts the amount of VBC revenue we receive. Attributed Lives increased 11.1% as of March 31, 2025 compared to March 31, 2024, due to our entrance into the Indiana market, as well as organic growth.

Current wording

We define Attributed Lives as any patient that a payer deems attributed to Privia to deliver care as part of a VBC arrangement through a provider of primary care services as of the end of a particular period. The number of Attributed Lives is an important measure that impacts the amount of VBC revenue we receive. Attributed Lives increased 15.2% as of June 30, 2025 compared to June 30, 2024, due to our entrance into the Indiana and Arizona markets, as well as organic growth.

Previous wording

We define Practice Collections as the total collections from all practices in all markets and all sources of reimbursement (FFS, VBC and other) that we receive for delivering care and providing our platform and associated services. Practice Collections differ from revenue by adding collections from Non-Owned Medical Groups. FFS arrangements accounted for 82.4% and 83.6% of our practice collections for the three months ended March 31, 2025 and 2024, respectively. VBC accounted for 17.4% and 16.2% of practice collections for the three months ended March 31, 2025 and 2024, respectively.

Current wording

We define Practice Collections as the total collections from all practices in all markets and all sources of reimbursement (FFS, VBC and other) that we receive for delivering care and providing our platform and associated services. Practice Collections differ from revenue by adding collections from Non-Owned Medical Groups. FFS arrangements accounted for 81.5% and 83.3% of our practice collections for the three months ended June 30, 2025 and 2024, respectively, and 81.9% and 83.5% for thesix months ended June 30, 2025 and 2024, respectively. VBC accounted for 18.3% and 16.4% of practice collections for the three months ended June 30, 2025 and 2024, respectively, and 17.8% and 16.3% for thesix months ended June 30, 2025 and 2024, respectively.

Previous wording

Practice Collections increased 12.8% for the three months ended March 31, 2025 when compared to the same period in 2024, mainly due to organic growth of our healthcare delivery business and our entrance into the Indiana market.

Current wording

Practice Collections increased 18.5% for the three months ended June 30, 2025 when compared to the same period in 2024, and 15.7% for thesix months ended June 30, 2025 compared to the same period in 2024, primarily mainly due to organic growth of our healthcare delivery business and our entrance into the Indiana and Arizona markets.

Previous wording

We define Care Margin as Gross Profit excluding amortization of intangible assets. Gross Profit is defined as total revenue less provider expenses and amortization of intangible assets. Our Care Margin generated from FFS revenue is contractual and recurring in nature, and primarily based on an individually negotiated percentage of collections for each practice that joins Privia. Our Care Margin generated from VBC revenue is based on a percentage of care management fees and shared savings collected. We view Care Margin as all of the dollars available for us to manage our business, including providing administrative support to our practices, investing in sales and marketing to attract new providers to the Privia Platform, and supporting the organization through our corporate infrastructure. We expect Care Margin will grow year-over-year in absolute dollars as we continue to expand our provider base. We would also expect our care management and shared savings economics in our VBC arrangements to improve on a per patient basis as we manage towards lower total cost of care for our Attributed Lives and move towards higher risk/higher reward VBC arrangements over time. Care Margin increased 10.9% for the three months ended March 31, 2025 when compared to the same period in 2024 due to organic growth of our medical practice business. As a percentage of revenue, Care Margin decreased to 21.9% for the three months ended March 31, 2025 from 22.9% for the same period in 2024. We continue to make strategic investments to provide better service to both our patients and physicians at a pace slower than the increase in revenue.

Current wording

We define Care Margin as Gross Profit excluding amortization of intangible assets. Gross Profit is defined as total revenue less provider expenses and amortization of intangible assets. Our Care Margin generated from FFS revenue is contractual and recurring in nature, and primarily based on an individually negotiated percentage of collections for each practice that joins Privia. Our Care Margin generated from VBC revenue is based on a percentage of care management fees and shared savings collected. We view Care Margin as all of the dollars available for us to manage our business, including providing administrative support to our practices, investing in sales and marketing to attract new providers to the Privia Platform, and supporting the organization through our corporate infrastructure. We expect Care Margin will grow year-over-year in absolute dollars as we continue to expand our provider base. We would also expect our care management and shared savings economics in our VBC arrangements to improve on a per patient basis as we manage towards lower total cost of care for our Attributed Lives and move towards higher risk/higher reward VBC arrangements over time. Care Margin increased 15.4% for the three months ended June 30, 2025 when compared to the same period in 2024 and increased 13.2% for thesix months ended June 30, 2025 when compared to the same period in 2024 due to organic growth of our medical practice business. As a percentage of revenue, Care Margin decreased to 22.1% for the three months ended June 30, 2025 from 23.6% for the same period in 2024 and decreased to 22.0% for thesix months ended June 30, 2025, compared to 23.2% during the same period in 2024. We continue to make strategic investments to provide better service to both our patients and physicians at a pace slower than the increase in revenue.

Previous wording

We define Platform Contribution as Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform. The following table provides a reconciliation of gross profit, the most closely comparable GAAP financial measure, to Platform Contribution. We consider Platform Contribution to be an important measure to monitor our performance, specific to pricing of our services, direct costs of delivering care, and cost of our platform and associated services. As a provider spends a longer time on the Privia Platform, we expect the Platform Contribution from that provider to increase both in terms of absolute dollars as well as a percent of Care Margin. We expect that this increase will be driven by improving per provider revenue economics over time as well as our ability to generate operating leverage on our in-market infrastructure costs. Platform Contribution increased 15.6% for the three months ended March 31, 2025 when compared to the same period in 2024 due to organic growth of our medical practice business and new market entry.

Current wording

We define Platform Contribution as Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform. The following table provides a reconciliation of gross profit, the most closely comparable GAAP financial measure, to Platform Contribution. We consider Platform Contribution to be an important measure to monitor our performance, specific to pricing of our services, direct costs of delivering care, and cost of our platform and associated services. As a provider spends a longer time on the Privia Platform, we expect the Platform Contribution from that provider to increase both in terms of absolute dollars as well as a percent of Care Margin. We expect that this increase will be driven by improving per provider revenue economics over time as well as our ability to generate operating leverage on our in-market infrastructure costs. Platform Contribution increased 21.3% for the three months ended June 30, 2025 when compared to the same period in 2024, and increased 18.5% for thesix months ended June 30, 2025 when compared to the same period in 2024, in each case due to organic growth of our medical practice business and new market entry.

Previous wording

We define Platform Contribution Margin as Platform Contribution as a percentage of Care Margin. We consider Platform Contribution Margin to be an important measure to monitor our performance, specific to pricing of our services, direct costs of delivering care, and cost of our platform and associated services. As a provider spends a longer time on the Privia Platform, we expect the Platform Contribution from that provider to increase both in terms of absolute dollars as well as a percent of Care Margin. We expect that this increase will be driven by improving per provider revenue economics over time as well as our ability to generate operating leverage on our in-market infrastructure costs. Platform Contribution Margin was 49.1% for three months ended March 31, 2025 compared to 47.1% during the same period in 2024. We continue to make strategic investments to provide better service to both our patients and physicians at a pace slower than the increase in revenue.

Current wording

We define Platform Contribution Margin as Platform Contribution as a percentage of Care Margin. We consider Platform Contribution Margin to be an important measure to monitor our performance, specific to pricing of our services, direct costs of delivering care, and cost of our platform and associated services. As a provider spends a longer time on the Privia Platform, we expect the Platform Contribution from that provider to increase both in terms of absolute dollars as well as a percent of Care Margin. We expect that this increase will be driven by improving per provider revenue economics over time as well as our ability to generate operating leverage on our in-market infrastructure costs. Platform Contribution Margin was 49.9% for three months ended June 30, 2025 compared to 47.5% during the same period in 2024, and 49.5% for the six months ended June 30, 2025 compared to 47.3% during the same period in 2024. We continue to make strategic investments to provide better service to both our patients and physicians at a pace slower than the increase in revenue.

Previous wording

We define Adjusted EBITDA as net income excluding interest income, interest expense, non-controlling expense / income, depreciation and amortization, stock-based compensation, severance, other one time or non-recurring expenses, employer taxes on equity vesting/exercises and the provision for income taxes. We include Adjusted EBITDA because it is an important measure by which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not reflect the impact of stock-based compensation expense, and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted EBITDA increased 35.1% for the three months ended March 31, 2025, when compared to the same period in 2024 due to organic growth of our medical practice business, growth in Attributed Lives, and growth in our value based care business.

Current wording

We define Adjusted EBITDA as net income excluding interest income, interest expense, non-controlling expense / income, depreciation and amortization, stock-based compensation, severance, other one time or non-recurring expenses, employer taxes on equity vesting/exercises and the provision for income taxes. We include Adjusted EBITDA because it is an important measure by which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not reflect the impact of stock-based compensation expense, and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted EBITDA increased 31.6% for the three months ended June 30, 2025, when compared to the same period in 2024, and 33.3% for thesix months ended June 30, 2025 compared to the same period in 2024, in each case due to organic growth of our medical practice business, growth in Attributed Lives, and growth in our value based care business.

Previous wording

We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of Care Margin. We included Adjusted EBITDA Margin because it is an important measure by which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA Margin was 25.6% for three months ended March 31, 2025 an increase from 21.0% for the same period in 2024 due to organic growth of our medical practice business and growth in our value based care business.

Current wording

We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of Care Margin. We included Adjusted EBITDA Margin because it is an important measure by which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin to be an important measure because it helps illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA Margin was 25.2% for the three months ended June 30, 2025 an increase from 22.1% for the same period in 2024, and 25.4% for thesix months ended June 30, 2025, andincrease from 21.5% for the same period in 2024, due to organic growth of our medical practice business and growth in our value based care business.

Previous wording

The following table sets forth our condensed consolidated statements of operations data for the three months ended March 31, 2025 and 2024:

Current wording

The following table sets forth our condensed consolidated statements of operations data for the three and six months ended June 30, 2025 and 2024:

Previous wording

Revenue was $480.1 million for the three months ended March 31, 2025, an increase from $415.2 million for the three months ended March 31, 2024. Key drivers of this revenue growth include: FFS–patient care revenue and FFS-administrative services, which increased $36.9 million and $3.2 million, primarily attributable to the addition of new providers and increase in visit volume; an increase in capitated revenue of $19.4 million due to an increase in Attributed Lives related to capitated arrangements; an increase in PMPM revenue of $4.6 million primarily due to increased Attributed Lives; and an increase in shared savings revenue of $0.4 million during the three months ended March 31, 2025 primarily due to timing of certain shared savings accruals and settlements, an increase in Attributed Lives in Medicare programs and continued strong performance in our value based care programs in the aggregate.

Current wording

Revenue was $521.2 million for the three months ended June 30, 2025, an increase from $422.3 million for the three months ended June 30, 2024. Key drivers of this revenue growth include: FFS–patient care revenue and FFS-administrative services, which increased $55.7 million and $3.0 million, primarily attributable to the addition of new providers and increase in visit volume; an increase in shared savings revenue of $20.2 million during the three months ended June 30, 2025 primarily due to timing of certain shared savings accruals and settlements; an increase in capitated revenue of $19.1 million due to an increase in Attributed Lives related to capitated arrangements; and an increase in PMPM revenue of $0.7 million primarily due to increased Attributed Lives, an increase in Attributed Lives in Medicare programs and continued strong performance in our value based care programs in the aggregate.

Previous wording

Provider expenses were $374.8 million for the three months ended March 31, 2025 compared to $320.3 million for the same period in 2024. The increase was driven primarily by higher FFS-patient care revenue and growth in Implemented Providers during the first quarter of 2025.

Current wording

Provider expenses were $406.0 million for the three months ended June 30, 2025 compared to $322.5 million for the same period in 2024, and $780.8 million for the six months ended June 30, 2025 compared to $642.9 million for the same period in 2024. The increase was driven primarily by higher FFS-patient care revenue and growth in Implemented Providers during 2025.

Previous wording

Cost of platform expenses were $59.5 million for the three months ended March 31, 2025 compared to $54.1 million for the same period in 2024. The increase was driven by an increase in stock-based compensation expense of $2.1 million, primarily related to an increase in stock-based awards granted in 2025 compared to 2024, and an increase in salaries and benefits of $1.5 million related to continued growth during the three months ended March 31, 2025 compared the same period in 2024.

Current wording

Cost of platform expenses were $64.9 million for the three months ended June 30, 2025 compared to $57.1 million for the same period in 2024. The increase was driven by an increase in salaries and benefits of $3.5 million related to continued growth during the three months ended June 30, 2025 compared the same period in 2024 and an increase in stock-based compensation expense of $2.5 million, primarily related to an increase in stock-based awards granted in 2025 compared to 2024.

Previous wording

Sales and marketing expenses were $6.9 million for the three months ended March 31, 2025 compared to $6.1 million for the same period in 2024. The increase was primarily driven by an increase in salaries and benefits of $0.7 million during the three months ended March 31, 2025 compared to the same period in 2024.

Current wording

Sales and marketing expenses were $6.8 million for the three months ended June 30, 2025 compared to $6.9 million for the same period in 2024. The decrease was primarily driven by various immaterial costs.

Previous wording

General and administrative expenses were $31.7 million for the three months ended March 31, 2025 compared to $32.1 million for the same period in 2024. The decrease was driven by the decrease of non-recurring expenses of $4.7 million partially offset by an increase of $3.4 million in stock-based compensation expense, which is primarily attributed an increase in stock-based awards granted in 2025 compared to 2024 and an increase in salaries and benefits of $1.0 million.

Current wording

General and administrative expenses were $37.5 million for the three months ended June 30, 2025 compared to $28.9 million for the same period in 2024. The increase was driven by an increase in salaries and benefits of $2.0 million, an increase of $2.6 million in professional services, an increase of non-recurring expenses of $1.8 million, and an increase of $1.5 million in stock-based compensation expense which is primarily attributed an increase in stock-based awards granted in 2025 compared to 2024.

Previous wording

Depreciation and amortization expenses were $1.9 million for the three months ended March 31, 2025 compared to $1.8 million for the same period in 2024. This increase was primarily driven by amortization of intangible assets related to an acquisition in 2024.

Current wording

Depreciation and amortization expenses were $2.6 million for the three months ended June 30, 2025 compared to $1.8 million for the same period in 2024, and $4.5 million for the six months ended June 30, 2025 compared to $3.6 million for the same period in 2024. This increase was primarily driven by amortization of intangible assets related to an acquisition in 2024.

Previous wording

Interest income was $2.9 million for the three months ended March 31, 2025 compared to $3.0 million for the same period in 2024. Interest income is primarily based on the cash balance held in interest bearing accounts.

Current wording

Interest income was $2.4 million for the three months ended June 30, 2025 compared to $3.0 million for the same period in 2024, and $5.3 million for the six months ended June 30, 2025 compared to $6.0 million for the same period in 2024. Interest income is primarily based on the cash balance held in interest bearing accounts.

Previous wording

The provision for income taxes was $2.1 million for the three months ended March 31, 2025, compared to the provision for income taxes of $0.8 million for the same period in 2024. The change was primarily attributable to reduced tax benefits stemming from share-based compensation related to stock option exercises and restricted stock unit vesting events.

Current wording

The provision for income taxes was $2.5 million for the three months ended June 30, 2025, compared to the provision for income taxes of $3.4 million for the same period in 2024. The change was primarily attributable to additional tax benefits stemming from share-based compensation related to stock option exercises and restricted stock unit vesting events.

Previous wording

Net income attributable to non-controlling interests was $1.8 million for the three months ended March 31, 2025 compared to $0.1 million during the same period in 2024. The change is primarily related to the continued growth in new markets entered.

Current wording

Net income attributable to non-controlling interests was $0.6 million for the three months ended June 30, 2025 compared to $1.2 million during the same period in 2024, and $2.4 million for the six months ended June 30, 2025, an increase compared to a net income of $1.2 million during the same period in 2024. The change is primarily related to the continued growth in new markets entered.

Previous wording

To date, we have financed our operations principally through sale of our equity, payments received from various payers and through borrowings under the prior Credit Agreement. As of March 31, 2025, we had cash and cash equivalents of $469.3 million. Our cash and cash equivalents primarily consist of highly liquid investments in money market funds and cash.

Current wording

To date, we have financed our operations principally through sale of our equity, payments received from various payers and through borrowings under the prior Credit Agreement. As of June 30, 2025, we had cash and cash equivalents of $390.1 million. Our cash and cash equivalents primarily consist of highly liquid investments in money market funds and cash.

Previous wording

Net cash used in operating activities was $24.1 million for the three months ended March 31, 2025, a decrease from $33.1 million for the same period in 2024. Significant changes impacting net cash used in operating activities for the three months ended March 31, 2025 compared to the same period in 2024 were as follows:

Current wording

Net cash used in operating activities was $16.1 million for the six months ended June 30, 2025, a decrease from net cash provided by operating activities of $1.3 million for the same period in 2024. Significant changes impacting net cash used in operating activities for the six months ended June 30, 2025 compared to the same period in 2024 were as follows:

Previous wording

•An increase in net income of $2.9 million compared to the same period in 2024. Net income was $6.0 million for the three months ended March 31, 2025 compared to income of $3.1 million for the same period in 2024.

Current wording

•An increase in net income of $1.6 million compared to the same period in 2024. Net income was $9.3 million for the six months ended June 30, 2025 compared to income of $7.7 million for the same period in 2024.

Previous wording

•An increase of $(73.4) million in accounts receivable and prepaid and other current assets, for the three months ended March 31, 2025 compared to the same period in 2024 of $(65.7) million, a difference of $(7.7) million. The change is primarily due to an increase in FFS and VBC revenue and timing of payments.

Current wording

•An increase of $(142.8) million in accounts receivable and prepaid and other current assets, for the six months ended June 30, 2025 compared to the same period in 2024 of $(81.0) million, a difference of $(61.8) million. The change is primarily due to an increase in FFS and VBC revenue and timing of payments.

Previous wording

•An increase of $35.7 million in provider liability for the three months ended March 31, 2025 compared to an increase of $24.2 million during the same period in 2024, a difference of $11.5 million. The increase is primarily due to an increase in Implemented Providers and an increase in provider expenses related to the increase in FFS and VBC revenue.

Current wording

•An increase of $81.2 million in provider liability for the six months ended June 30, 2025 compared to an increase of $40.0 million during the same period in 2024, a difference of $41.2 million. The increase is primarily due to an increase in Implemented Providers and an increase in provider expenses related to the increase in FFS and VBC revenue.

Previous wording

Net cash used in investing activities was de minimis for the three months ended March 31, 2025 compared to $5.7 million during the same period in 2024, primarily due to business acquisitions and other investing activities during the first quarter of 2024.

Current wording

Net cash used in investing activities was $89.1 million for the six months ended June 30, 2025 compared to $5.7 million during the same period in 2024, primarily due to business acquisitions during the second quarter of 2025.

Previous wording

Net cash provided by financing activities was $2.2 million for the three months ended March 31, 2025, an increase from net cash provided of $0.5 million for financing activities for the same period in 2024. The increase is primarily due to an increase in proceeds from stock options exercised during the three months ended March 31, 2025.

Current wording

Net cash provided by financing activities was $4.1 million for the six months ended June 30, 2025, an increase from $2.2 million for financing activities for the same period in 2024. The increase is primarily due to an increase in proceeds from stock options exercised during the six months ended June 30, 2025.

Previous wording

Operating Leases. The Company leases office space under various operating lease agreements. The initial terms of these leases range from 2 to 9 years and generally provide for periodic rent increases, renewal, and termination operations. Total rent expense under operating leases was $0.7 million for both the three months ended March 31, 2025 and 2024.

Current wording

Operating Leases. The Company leases office space under various operating lease agreements. The initial terms of these leases range from 2 to 9 years and generally provide for periodic rent increases, renewal, and termination operations. Total rent expense under operating leases was $0.7 million and $0.8 million for each of the three months ended June 30, 2025 and 2024, and $1.4 million for each of the six months ended June 30, 2025 and 2024, respectively

Previous wording

There have been no changes to the critical accounting policies reported in the Annual Report that affect our significant judgments and estimates used in the preparation of our Condensed Consolidated Financial Statements.

Current wording

There have been no changes to the critical accounting policies reported in the 2024 Annual Report that affect our significant judgments and estimates used in the preparation of our Condensed Consolidated Financial Statements other than those discussed below.